Vitalhub - CEO, Dan Matlow.
CEO, Dan Matlow.
Source: LinkedIn.
  • VitalHub (VHI) has signed a three-year licensing contract with University Hospitals Dorset NHS Foundation Trust
  • Subsidiary Intouch with Health will expand its patient flow solutions to cover the trust’s three hospitals
  • This marks the 9th Intouch contract announced this quarter
  • VitalHub offers technology solutions to health and human services providers
  • VitalHub (VHI) is up by 1.27 per cent trading at $3.18 per share

VitalHub (VHI) has signed a three-year licensing contract with the NHS.

The contract pertains to University Hospitals Dorset NHS Foundation Trust, which manages three hospitals in Southeast Dorset – Royal Bournemouth, Poole and Christchurch – and serves a population of more than 800,000 people through 9,000 dedicated staff members.

Subsidiary Intouch with Health will expand its patient flow solutions to Bournemouth and Christchurch to cover the trust’s three hospitals. Solutions include flow manager, check in, calling, wait times and mobile functionality.

This marks the 9th Intouch contract announced this quarter.

“Expansion agreements such as this contract with University Hospitals Dorset NHS Foundation Trust affirm the value our customers derive from our products and services,” said Dan Matlow, VitalHub’s CEO. “With this deal, we expand upon our strong existing footprint across the NHS. We look forward to deepening our relationship with Dorset as we further execute on our growth strategy and health IT leadership.”

VitalHub offers technology solutions to health and human services providers.

VitalHub (VHI) is up by 1.27 per cent trading at $3.18 per share as of 2:53 pm EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.